163.63 USD
+0.29 (+0.18%)
164.21 USD
+0.58 (+0.35%)
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year RGEN was profitable.
- RGEN had a positive operating cash flow in the past year.
- RGEN had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
- RGEN's Return On Assets of 0.06% is fine compared to the rest of the industry. RGEN outperforms 68.97% of its industry peers.
- With a decent Return On Equity value of 0.08%, RGEN is doing good in the industry, outperforming 70.69% of the companies in the same industry.
- With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
- RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
- The Profit Margin of RGEN (0.25%) is better than 68.97% of its industry peers.
- RGEN has a better Operating Margin (6.58%) than 62.07% of its industry peers.
- RGEN's Operating Margin has declined in the last couple of years.
- RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 58.62% of its industry peers.
- In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
- RGEN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, RGEN has more shares outstanding
- The debt/assets ratio for RGEN has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 7.48 indicates that RGEN is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 7.48, RGEN belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
- RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
- RGEN's Debt to FCF ratio of 5.05 is fine compared to the rest of the industry. RGEN outperforms 67.24% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
- RGEN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: RGEN outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.48 |
ROIC/WACC0.1
WACC10.73%
2.3 Liquidity
- RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 8.36, RGEN belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
- A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
- RGEN has a Quick ratio of 7.14. This is amongst the best in the industry. RGEN outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.17% over the past year.
- Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
- The Revenue has decreased by -8.54% in the past year.
- Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
- The Earnings Per Share is expected to grow by 24.54% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 15.92% on average over the next years. This is quite good.
EPS Next Y14.84%
EPS Next 2Y19.33%
EPS Next 3Y22.24%
EPS Next 5Y24.54%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.31%
Revenue Next 5Y15.92%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 98.57, which means the current valuation is very expensive for RGEN.
- The rest of the industry has a similar Price/Earnings ratio as RGEN.
- When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (28.82), we can say RGEN is valued expensively.
- A Price/Forward Earnings ratio of 77.64 indicates a quite expensive valuation of RGEN.
- The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
- RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 25.95, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.57 | ||
| Fwd PE | 77.64 |
4.2 Price Multiples
- RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 86.5 | ||
| EV/EBITDA | 81.1 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- RGEN's earnings are expected to grow with 22.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.64
PEG (5Y)13.87
EPS Next 2Y19.33%
EPS Next 3Y22.24%
5. Dividend
5.1 Amount
- No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.